Area of research
Radiology, Nuclear Medicine and Imaging · Epidemiology
Research interest
Research interests include Medical Imaging Techniques and Applications, Radiopharmaceutical Chemistry and Applications, Radiomics and Machine Learning in Medical Imaging, and Neuroendocrine Tumor Research Advances.
Simultaneous [¹⁵O]H₂O and [⁸⁹Zr]mAb Scanning With Long Axial Field-of-View PET: A Simulation Study Using Digital Twins
Delayed [<sup>89</sup>Zr]Zr-<i>N</i>-Succinyldesferal-Trastuzumab Imaging Enabled by Long-Axial-Field-of-View PET/CT.
Separation of simultaneously acquired [<sup>89</sup>Zr]atezolizumab and [<sup>18</sup>F]FDG PET scans.
Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer.
Author Correction: Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.
Smart scanning for two: [<sup>18</sup>F]FDG dose optimization for pregnant patients using LAFOV PET/CT technology.
[18F]FDG PET/CT to reduce the need for sentinel lymph node biopsy in early-stage oral cancer: PETN0-study protocol.
Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy.
The value of <sup>18</sup>F-FDG PET/CT and <sup>18</sup>F-DOPA PET/CT in determining the initial surgical strategy of patients with medullary thyroid cancer : Preoperative PET/CT imaging for medullary thyroid cancer.
Influence of Ultra-Low-Dose CT on PET Image Quantification and Visual Assessment.
Toxicity and Quality of Life After Locoregional Radiotherapy in Patients With Thyroid Cancer.
Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer.
Quantification of <sup>89</sup>Zr-immunoPET: Methodological considerations.
The utility of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in predicting the response to tyrosine kinase inhibitors in patients with advanced medullary thyroid cancer.
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Supplement LASSO from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Supplementary Figure S3 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Supplementary Figure S2 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Supplementary Figure S1 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
Ultra-low dose CT scanning for PET/CT.
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer
Ultrashort Oncologic Whole-Body [<sup>18</sup>F]FDG Patlak Imaging Using LAFOV PET.
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
Improved Localization of Insulinomas Using <sup>68</sup>Ga-NODAGA-Exendin-4 PET/CT.
Advances and challenges in immunoPET methodology.
Head-to-head comparison of [<sup>11</sup>C]methionine PET, [<sup>11</sup>C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism.
How nuclear imaging changed parathyroid surgical strategies through time.